16 unknown, 11 recruiting, 8 completed, 5 active not recruiting. 47 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 47 | Unknown 16, Recruiting 11, Completed 8, Active not recruiting 5, Not yet recruiting 4, Terminated 2, Suspended 1 |
| Phase 1 | 3 | Terminated 2, Completed 1 |
Follow Locally Advanced Rectal Cancer: new trials by email Literature Review of Locally Advanced Rectal Cancer trials Research Report on Locally Advanced Rectal Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer Nivolumab, HDRBET, Total Mesorectal Excision (TME) - Locally Advanced Rectal Cancer | Phase 2 | Recruiting | Dr. Te Vuong | 10 | 2026-10-01 | 2026-10-28 |
| Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer Modified Short-course radiotherapy, Long-course radiotherapy, Oxaliplatin - Locally Advanced Rectal Cancer | Phase 2 | Recruiting | Fujian Cancer Hospital | 130 | 2026-08-15 | 2026-10-01 |
| A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer Camrelizumab - Locally Advanced Rectal Cancer | Phase 2 | Recruiting | Chinese PLA General Hospital | 44 | 2026-02-01 | 2026-04-14 |
| A Phase II Single-Arm Study of High-Bioavailability Curcumin as Neoadjuvant Chemoradiotherapy in Mid-to-Low Rectal Cancer: Integrated Clinical and Translational Analysis of Tumor Tissue Curcumin (BCM-95®) - Rectal Cancer, Locally Advanced Rectal Cancer | Phase 2 | Not yet recruiting | Chang Gung Memorial Hospital | 72 | 2026-01-01 | 2025-11-25 |
| Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC) Long-course radiotherapy, Oxaliplatin, Capecitabine - Locally Advanced Rectal Cancer, Neoadjuvant Therapy | Phase 2 | Recruiting | Fudan University | 138 | 2025-08-28 | 2025-09-02 |
| Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I) Capecitabine, Camrelizumab, CAPOX - Locally Advanced Rectal Cancer | Phase 2 | Suspended | Hebei Medical University Fourth Hospital | 90 | 2025-07-01 | 2026-07-31 |
| Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer Ivonescimab (SMT112 or AK112) Injection - Locally Advanced Rectal Cancer | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Zhengzhou University | 40 | 2025-01-20 | 2025-01-08 |
| Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer short-course radiotherapy, Ivonescimab, capecitabine - Locally Advanced Rectal Cancer, Neoadjuvant Therapy | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 45 | 2024-10-16 | 2025-01-31 |
| MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer PD-1 antibody, Oxaliplatin, Capecitabine - Locally Advanced Rectal Cancer | Phase 2 | Recruiting | Fudan University | 46 | 2024-08-13 | 2025-02-21 |
| Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer Long-course chemoradiation and PD-1 inhibitor, with PCSK9 inhibitor, Long-course chemoradiation and PD-1 inhibitor, without PCSK9 inhibitor - Locally Advanced Rectal Cancer | Phase 2 | Unknown | Beijing Friendship Hospital | 50 | 2024-04-01 | 2024-03-19 |
| CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer PD-1 inhibitor, Capecitabine, Short-course radiotherapy - Locally Advanced Rectal Cancer, Neoadjuvant Therapy | Phase 2 | Recruiting | Fudan University | 192 | 2024-03-28 | 2026-04-03 |
| Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer node-sparing short-course radiotherapy, Sintilimab, Capecitabine - Locally Advanced Rectal Cancer | Phase 2 | Recruiting | Jinhua Central Hospital | 37 | 2024-02-05 | 2026-04-24 |
| Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer capecitabine, tislelizumab, thymalfasin - Locally Advanced Rectal Cancer | Phase 2 | Active not recruiting | Beijing Friendship Hospital | 20 | 2024-01-03 | 2025-04-02 |
| Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study Fruquintinib, Adebrelimab, Oxaliplatin, Capecitabine - Locally Advanced Rectal Cancer | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 45 | 2023-12-01 | 2024-03-18 |
| Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer AK104, Capecitabine, Neoadjuvant Radiotherapy - Locally Advanced Rectal Cancer | Phase 2 | Unknown | Sun Yat-sen University | 33 | 2023-10-24 | 2024-02-07 |
| Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study nCRT → (CapeOX+Sintilimab)×6 → Surgery/W&W - Locally Advanced Rectal Cancer, Total Neoadjuvant Treatment | Phase 2 | Not yet recruiting | The First Hospital of Jilin University | 45 | 2023-09-01 | 2023-08-18 |
| CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer Capecitabine, Oxaliplatin, Bevacizumab - Locally Advanced Rectal Cancer | Phase 2 | Active not recruiting | Shanghai Changzheng Hospital | 30 | 2023-05-01 | 2026-09-02 |
| Assess the Efficacy of Radiotherapy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CRC（AK104-IIT-13） AK104 injection, TME surgery, Capecitabine - Locally Advanced Rectal Cancer | Phase 2 | Not yet recruiting | JIN JING | 50 | 2023-04-24 | 2023-04-06 |
| Neoadjuvant Long-course Chemoradiotherapy Followed by Immunotherapy for Locally Advanced Mid-low Rectal Cancer radiation, PD-1 Monoclonal Antibody, TME surgery - Locally Advanced Rectal Cancer | Phase 2 | Completed | Peking University People's Hospital | 30 | 2023-01-01 | 2025-11-25 |
| TIME in Immunotherapy Combined With nCRT for Rectal Cancer PD-1 inhibitor, Capecitabine, Long-course radiation therapy - Locally Advanced Rectal Cancer | Phase 2 | Active not recruiting | Peking Union Medical College Hospital | 100 | 2022-12-20 | 2026-07-07 |
Showing 20 of 47. Sign in to see all of them.
Rectal Neoplasms (10) · Colorectal Neoplasms (3) · Hyperthermia (1) · Neoplasms (1) · Neoplastic Processes (1) · Pathologic Complete Response (1) · Pathologic Processes (1) · Postoperative Complications (1)
Digestive System Diseases (12) · Digestive System Neoplasms (12) · Gastrointestinal Diseases (12) · Gastrointestinal Neoplasms (12) · Intestinal Diseases (12) · Intestinal Neoplasms (12) · Neoplasms by Site (12) · Rectal Diseases (12) · Neoplasms (11) · Colorectal Neoplasms (9) · Colonic Diseases (3) · Pathological Conditions, Signs and Symptoms (3) · Pathologic Processes (2) · Body Temperature Changes (1) · Disease Attributes (1)
Capecitabine (23) · Oxaliplatin (15) · Irinotecan (6) · spartalizumab (6) · Immune Checkpoint Inhibitors (5) · tislelizumab (5) · Radiotherapy (4) · Bevacizumab (3) · Fluorouracil (3) · Neoadjuvant Therapy (3) · Radiation (3) · sintilimab (3) · toripalimab (3) · Celecoxib (2) · HMPL-013 (2)
Fudan University (8) · Beijing Friendship Hospital (4) · First Affiliated Hospital of Zhejiang University (2) · Hebei Medical University Fourth Hospital (2) · Institute of Oncology Ljubljana (2) · Sun Yat-sen University (2) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2) · Zhejiang Cancer Hospital (2) · Aiping Zhou (1) · Ali Shamseddine (1) · Cancer Trials Ireland (1) · Chang Gung Memorial Hospital (1) · Chinese PLA General Hospital (1) · Dr. Te Vuong (1) · EMD Serono Research & Development Institute, Inc. (1)
China (31) · Germany (2) · Slovenia (2) · Taiwan (2) · Belgium (1) · Canada (1) · Denmark (1) · Ireland (1) · Italy (1) · Jordan (1) · Lebanon (1) · South Korea (1) · Spain (1) · United States (1)
Zhen Zhang, M.D, PH.D (3) · Zhen Zhang, MD (3) · Aiping Zhou, Doctor (1) · Alexander Stein (1) · Ali I Shamseddine, M.D. (1) · Chunkang Yang, MD (1) · Dr Brian O'Neill, MD (1) · Eric Van Cutsem, Prof. Dr. (1) · Fengpeng Wu (1) · Guanghai Dai, MD (1) · Haiyang Zhou, MD (1) · Jiaolin Zhou, Ph.D (1) · Jiunluan Li, MD (1) · Julie Gehl, MD, DMSc (1)
PMID 19594223, PMID 19735878, PMID 20046768, PMID 20726007, PMID 30968152, PMID 31108984, PMID 32029014, PMID 32264919, PMID 32873251, PMID 32891715, PMID 33028346, PMID 33741467, PMID 35291966, PMID 37370032, PMID 37699634, PMID 38641773, PMID 38950321, PMID 39003182, PMID 39693793, PMID 39762418, PMID 40860797, PMID 40876501, PMID 41222702, PMID 42495710
2018 (1)